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Summary
Background A successful outcome of pregnancy requires an
efficient uteroplacental vascular System Smce this System
may be compromised by disorders of haemostasis
associated with a prothrombotic state we postulated that
maternal thrombophilia might be a nsk factor for fetal loss
We studied the relation between heritable thrombophihc
defects and fetal loss m a cohort of women with factor V
Leiden or deficiency of antithrombm protem C or protem S
Methode We studied 1384 women enrolled m the European
Prospective Cohort on Thrombophilia (EPCOT) Of 843
women with thrombophilia 571 had 1524 pregnancies of
541 control women 395 had 1019 pregnancies The
controls were partners of male members of the EPCOT
cohort or acquamtances of cases We analysed the
frequencies of miscarnage (fetal loss at or before 28 weeks
of gestation) and stillbirth (fetal loss after 28 weeks of
gestation) jomtly and separately
Fmdings The nsk of fetal loss was mcreased m women with
thrombophilia (168/571 vs 93/395 odds ratio 135
[95% Cl l 01-1 82]) The odds ratio was higher for stillbirth
than for miscarnage (3 6 [l 4-9 4] vs l 27 [0 94-1 71])
The highest odds ratio for stillbirth was m women with
combmed defects (143 [24-860]) compared with 5 2
(15-181) m antithrombm deficiency 23 (06-83) m
protem C deficiency 3 3 ( 1 0-11 3) m protem S deficiency
and 2 0 ( 0 5-7 7) with factor V Leiden The correspondmg
odds ratios for miscarnage m these subgroups were 0 8
(02-36) 17(10-28) 14(09-22) 12(07-19) and
0 9 ( 0 5-1 5) Significantly more pregnancy termmations
had been done m women with thrombophilia than m controls
(odds ratio 2 9 [l 8-4 8]) this discrepancy was apparent m
nme of 11 participatmg centres and for all thrombophilia
subgroups
Interpretation Women with familial thrombophilia
especially those with combmed defects or antithrombm
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deficiency have an mcreased nsk of fetal loss particularly
stillbirth Our fmdmgs have important implications for
therapy and provide a rationale for clmical trials of
thromboprophylaxis for affected women with recurrent fetal
loss
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Introduction
Until lately, a clear relation with a genetic thrombophihc
defect was evident m only 5-10% of patients presentmg
with venous thromboembohsm and was confmed to those
with deficiencies of antithrombin, protem C, and protem
S The importance of heritable defects äs nsk factors for
venous thromboembohsm has mcreased with the
discovery of a genetic thrombophihc disorder that
mamfests äs resistance to activated protem C (APC)' and
the observation that this disorder is present m about 20%
of mdividuals presentmg with venous thrombosis Bertma
and colleagues3 have shown that m most mdn iduals APC
resistance is the result of a single pomt mutation m the
factor V gene at nucleoude 1691, which codes for the
APC cleavage site (factor V Leiden mutation) In much of
Europe and m the USA the prevalence of the factor V
Leiden defect is 3-5% However, m other parts of the
world, such äs southeast Asia and Afnca, the pre\alence of
the defect is less than l % 4
In pregnancy, a successful outcome is highh dependent
on satisfactory placental development and sustamed
placental function These processes, m turn, require the
establishment of an adequate fetomaternal circulatorv
System Smce this System may be compromised b\
disturbances of haemostasis leadmg to a prothrombotic
state, we postulated that maternal thrombophilia might be
a nsk factor for fetal loss We have therefore studied the
relation between heritable thrombophihc deiects and fetal
loss m a cohort of women who ha\e factor V Leiden or
deficiencies of antithrombin, piotem C, or protem S (the
European Prospective Cohort on Thrombophilia
[EPCOT]) and m a control group Although EPCOT is i
prospectivc follow-up study, the data here were collected
at baselme and give Information on hfetime occurrence ot
miscarnage and stillbirth
Patients and methods
The women descnbed here were enrolled m LPCOF betueen
Januiry, 1994, and November 1995 The primm um ot the
btudy is to estabhsh the nsk ot thrombosis m this jroup ot
disorders A seeondary aim is> to imcsticite the possible relit ion
between these disorders and the nsL ot tet ü loss
The mdex gioup consists ot m ile irui lern ile indnidu ils ot ill
ages with or without SymptomUie dise ise Lieh p utieip itii~u
eentie enrolled all registered pi t ienls who h id heredi tm
thiomhophiln e lused by detieieneies ot protem C piotem S 01
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Women ever pregnant
Number of pregnancies
Number of pregnancies
endmg m miscarnage
Number of pregnancies
endmg m st llbirth
Number of women with
fetal losst
Number of pregnanc es
resultmg n fetal losst
Deflclendes of
Antithrombm
108
260
44(169%)
6 (2 3%)
34(315%)
50(192%)
Protein C
162
430
68 ( 15 8%)
5 ( 1 2%)
48 (29 6%)
73(170%)
Protein S
145
378
55 ( 14 6%)
7 ( 1 9%)
42 (290%)
62 (16 4%)
Factor V
Leiden
141
410
43(105%)
5(12%)
38(269%)
48(117%)
Combined
defects *
15
46
6 ( 13%)
7 ( 15%)
6(40%)
13(28%)
All patlents
571
1524
216(142%)
30 (2 0%)
168(294%)
246(16 1%)
Controls
395
1019
118(116%)
6 (0 6%)
93 (23 5%)
124(122%)
*4 protem C deficiency+factor V Leiden 7 protem S deficiency+factor V Leiden 2 antithrombm deficiency+factor V Leiden and 2 protem C and protem S deficiencies tExcIudes
terminations of pregnancy
Table l Number of pregnancies and fetal loss
antithrombm, or by factor V Leiden There were no exclusion
cntena Healthy controls are enrolled m the studv for reasons of
companson The patients were asked whether their spouses (or
Partners) would be wilhng to serve äs controls Smgle patients
were asked to find an acquamtance who would be wilhng to serve
äs a control We left the paüent to decide whether the control was
of the same sex or not Since the controls are partners (65%) or
acquamtances (35%) of the mdex individuals, the control group is
of about the same age äs the mdex group We excluded from the
control group blood relatives of the mdex panent and mdividuals
known to have famihal thrombophiha All data collection, at
basehne, and at follow-up was the same for the patients and
controls We report here the data collected at basehne, refernng
to events before entry to EPCOT
Before study enrolment, mformed consent was obtamed from
all mdividuals, mcludmg controls Data were collected at entry to
the study and annually thereafter, by questionnaire or by
telephone or personal interview Data recorded include general
demographic Information, thrombosis history, medicanon, nsk
factors for thrombosis, famüy history, obstetnc history, and
details on type and subtype of thrombophiha Standard data-
collection forms are used at all participating centres For each
panent, the diagnosis of hentable thrombophiha is confirmed by
the diagnostic cntena of the study protocol All contnbutmg
centres participate m an external quality-assessment scheme for
thrombophiha testing
We calculated the number of women m each group who had
been pregnant and analysed the outcome of all pregnancies—
miscarnage, pregnancy termmation, stillbirth, or livebirth
Miscarnage was defined äs fetal loss dunng the first or second
tnmester (le, up to and mcludmg 28 weeks' gestation) Stillbirth
was defined äs mtrauterme death dunng the third tnmester (le,
after 28 weeks' gestation) We could obtain Information only on
known or confirmed pregnancies We assessed differences m the
nsk of fetal loss by companng the number of women who had
ever expenenced miscarnage or stillbirth by cross-tabulation and
χ test We also compared the frequencies of pregnancy
termmation between the groups
The structure of the control group made study of the effect of
paternal thrombophiha on fetal loss possible For this report only
the women from EPCOT are mcluded äs patients, and the
controls are female partners of thrombophihc men, or unrelated
acquamtances of thrombophihc patients By companng the
frcquency of fetal loss m control women who are partners of
thrombophihc men and those who are not, we investigated the
effect of paternal thrombophiha on miscarnage and stillbirth
The mean number of pregnancies differed among the vanous
study groups, this differenee had to be taken mto account since
the nsk of fetal loss obviously mcreases with the number of
pregnancies We therefoie oarned out logistic regression analysis
with ever-expcnence of tetal loss äs the outcome (dependent)
variable and the total number of pregnancies äs one ot the
covuuitcs (inckptndent variable) When a variable of mtercst is
mc-luded m the modü (tor e\amplt, whether a woman is a
thiombophihc patii_nt or a t_ontrol), this regression analysis will
producc an odds ratio tor that variable This odds ratio is a
mi_nsun. ot relative nsk, and is tht ratio ot the odds ot tetal loss m
an mdex woman over the odds m a control woman, adjusted for
the number of pregnancies An odds ratio of more than one
mdicates a nsk exceedmg that of controls As a variable of mterest
we also looked at the type of thrombophiha, a dummy vanable
model gave separate odds ratlos, each compared with the
controls, for each subtvpe of thrombophiha Since the
participating centres are spread widely across Europe, and since
we investigated lifetime nsk of fetal loss and our study penod
encompassed several decades, we also assessed the effect of
adjustment for possible regional and time effects, by addmg
centre (äs a dummy vanable) and current age (äs a contmuous
term) mto the models used Since adjustment for age did not lead
to any change, this vanable was omitted from the models
presented We then investigated the effect of thrombophiha on
miscarnage and stillbirth separately To allow for the possibihty
that heterogeneity among women m other, unknown, factors
might affect the nsk of fetal loss, we also analysed the nsk of
pregnancies endmg m fetal loss by a random effects model
Results
Patients and controls were enrolled by 11 centres from
nme countnes (Leiden, Barcelona, Bologna, Frankfurt;
Glasgow, Malmo, Paris, Rome, Sheffield, Tel-Hashomer,
Vienna) On Nov l, 1995, 1384 women had been enrolled
(843 patients, 541 controls) Most of the controls (354
[65%]) were panners of mdex patients, this Proportion
was 79% (311/395) among the controls who had been
pregnant at least once The patients were 242 women with
protem-C deficiency, 214 with protem-S deficiency, 159
with antithrombm deficiency, 203 with the factor V
Leiden defect, and 25 with combmed defects 571 patients
had had 1524 pregnancies compared with 1019
pregnancies m 395 controls
Here we report on fetal loss among women who had
been pregnant at least once (571 patients—162 with
protem-C deficiencv, 145 with protem-S deficiency, 108
with antithrombm deficiency, 141 with the factor V
Leiden defect, and 15 with combmed defects) The mean
age of the 966 women who had been pregnant at least
once (571 patients, 395 controls) at enrolment was 46 2
years (ränge 20-92), the mean age was similar for patients
and controls (mean 45 7 [SD 138] vs 47 0 [12 2] years)
The number of pregnancies ranged from l to 14 (patients
1-14, controls 1-11) and the number of fetal losses per
Any fetal loss
Miscarnage
Stillbirth
Patients
(n=571)
168
154
25
Controls
(n=395)
93
89
5
Odds ratio (95% Cl)
1 35(101-182)
127(094-1 71)
36 (14 -94 )
Numbers of miscarnages and stillbirths do not add up to the numbers under any fetal
Idbs or overill figures m table l bince some women have expenenced miscarnages
and stillbirths
Table 2 Odds ratlos of fetal loss in women with thrombophiha
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Type
Antitrirombin defsciency
ProtenC deficiency
Protein S deficiency
Factor V Le den
Combmed defects
All spontaneous
fetal losses
21(12-36)
14(09-22)
13(08-2 1)
10(06-1 7)
20(05-81)
Mlscarrlage
17(10 28)
14(09-22)
12(07-19)
0 9 ( 0 5 15)
08(02-36)
Stlllblrth
5 2 ( 1 5-181)
23(06-83)
33(10 113)
2 0 ( 0 5-7 7)
143(24-860)
Table 3 Odds ratlos (95% Cl) for fetal loss and type of
thrombophilia, with control group äs reference, adjusted for
number of pregnancies and centre
woman ranged from 0 to 6 in both groups The mean
number of pregnancies u äs similar in patients and controls
(2 7 [l 7] vs 2 6 [l 4])
Fetal loss
Sigmficandy more women with thrombophilia than
controls had expenenced fetal loss (miscarnage or
stillbirth, table l, p=0 04) The odds ratio for fetal loss
associated with thrombophilia was l 35 (95% CI
l 01-1 82) Random effects modellmg led to a very similar
result (l 40 [l 04-1 90]) The percentage of pregnancies
endmg in fetal loss (with termmations of pregnancy
excluded) was significantly greater in each of the
subgroups of patients with deficiencies of antithrombin,
protein C, or protein S and m the subgroup with
combmed defects than in the control group The
percentage of pregnancies endmg m fetal loss in women
with factor V Leiden did not differ significantly from that
m the control group
For all women with thrombophilia compared with
controls the relative nsk of stillbirth was greater than that
for miscarnage (table 2)
We carned out logistic regression to adjust the nsk of
fetal loss m thrombophilia for differences m the number of
pregnancies Table 3 shows the odds ratios for both
stillbirths and miscarnages for women with each type of
thrombophilia and for those with combmed defects, with
the control group äs reference, adjusted for the number of
pregnancies and centre Further adjustment for age did
not affect the estimates The random effects model gave
essentially the same coefficients äs the fixed model The
odds of ever having had a spontaneous fetal loss were
30-36% greater m women with deficiencies of protein C
or protein S than in controls without thrombophilia and
200% higher in women with antithrombm deficiency or
with combmed defects than in controls After we had
adjusted for the higher number of pregnancies m carriers
of factor V Leiden, we no longer found an excess nsk of
fetal loss associated with this abnormality (odds ratio l 0
[0 6-1 7])
We repeated the multivanate analysis for miscarnages
and stillbirths äs separate outcomes, adjusted for the
number of pregnancies This analysis confirmed the more
pronounced odds ratio for stillbirths than for miscarnages
% of women with pregnancies endlng In fetal loss
Termmations mcluded Termmations excluded
Thrombophilic subgroup
Ant thronbin deficiency
Protein C deficiency
Protein S deficiency
Factor V Leiden
Combmed defects
Controls
49 l 315
38 3 29 6
40 7 29 0
376 269
46 7 40 0
286 235
Table 4 Percentage of women with pregnancies resulting in
fetal loss with and without termmations of pregnancy
but since there were fewer women with stillbirths than
with miscarnages the confidence intervals were wider For
all subtypes of thrombophilia the odds ratio for stillbirths
exceeded that for miscarnages Agam, we found no
indication of an excess nsk of miscamage in camers of
factor V Leiden However, an mcreased nsk of stillbirth in
camers of factor V Leiden does remam possible, although
the confidence interval of the odds ratio was wide (2 0
[0 5-7 7]) The odds ratio for stillbirth was higher for all
other subtypes of thrombophilia than for factor V Leiden
and agam highest in those with combmed defects
Terminat/on of pregnancy
15 8% of all the thrombophilic patients who had been
pregnant had had at least one induced termmation of
pregnancy compared with 61% of the control group
(p<0 001, χ" lest, odds ratio 2 9 [l 8-4 6]) An mcreased
frequency of pregnancy termmations compared with the
control group was seen m all the thrombophilic subgroups
(table 4) Since these observations could have been
influenced by differences between participatmg centres,
the data were reanalysed for each centre In nine of the
11 centres, termmations were more frequent among
thrombophilic women than among controls
Influence of patemal thrombophilia
Many female partners of men with known thrombophilia
have been enrolled m the EPCOT study control group
Since these thrombophilic disorders are transmitted with
an autosomal dominant pattern, we mvestigated the
pregnancy outcome m the 311 control women who had
been pregnant and were partners of men with
thrombophilia We compared their results with those for
84 control women who had been pregnant and whose
partners had no known thrombophilic defect There was
no difference in the number of pregnancies or fetal losses
between these two groups (data not shown)
Discussion
In this cross-sectional, multicentre study we found an
mcreased risk of fetal loss m women with hentable
deficiencies of antithrombm, protein C, or protein S The
nsks were greatest for women with antithrombm
deficiency and for those with combmed defects
Although the mcreased nsk of fetal loss was found for
both miscarnage and stillbirth, analysed jointlv and
separately, the effect of thrombophilia was especially
pronounced for stillbirths This finding is not unexpected
miscamage is a common event with many possible causes,
so positive Identification of mdividual causative factors is
difficult, whereas stillbirth is a much rarer event and
strong risk factors are more readily identifiable Since our
study dealt only with known or confirmed pregnancies, no
conclusions can be drawn on the possibihty of an effect of
thrombophilia on very early fetal loss
No mcreased nsk of fetal loss was evident in women
with factor V Leiden For this group, although there was
no excess of miscarnages, our results do suggest the
possibihty of an mcreased nsk of stillbirth We can,
however, conclude that the risk of total fetal loss is less
than that of the other thrombophilic groups
An mcreased frequency ot pregnancv termmations
among women with all types of thrombophilu, includmg
factor V Leiden, was tound m nine of the 11 pdrnupatmg
centres Overall, proportionately more women \ \ i t h tactor
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V Leiden than vvomen in the other groups had had
abortions This tactor may have influenced the number ot
obsened spontaneous fetal losses m these vvomen We did
not include these data in our analysis of fetal loss m
thrombophihc women, since we beheve that they relate to
maternal rather than to fetal conditions We cannot
identifv the reasons for the mcreased number of pregnancy
termmations but speculate that decisions to termmate
pregnancv might have been influenced by previous
episodes of venous thromboembohsm, occurrmg either
dunng pregnancy or in association with oral-contraceptive
use Conception dunng treatment with coumanns might
also have been a reason for termmation
Since we report on miscarnage and fetal loss assessed
retrospectively at the begmnmg of follow-up, we must
consider the possibility of recall bias—is, the tendency for
patients to recall past events more readily than do
controls A well-known example of recall bias is that
mothers of newborn mfants with biith defects are much
better able to remember mmor illnesses or drugs they took
dunng pregnancy than are mothers of healthy babies We
do not thmk that recall bias is hkely to be important m our
studv, since m this settmg thrombophilia is the mmor
event, and this diagnosis would be unlikely to make more
women remember miscarnage The possibility that the
diagnosis would affect the memory of a fetal loss occurrmg
after 28 weeks of gestation is mconceivable
The control group consisted of partners of
thrombophihc men and acquamtances of thrombophihc
mdividuals The mclusion of the latter type of controls
might theoretically lead to cases and controls bemg too
much ahke, which would lead to biased estimates
However, since only a small proportion of controls were
acquamtances of patients m this cohort, this bias can have
had only a shght effect If present, this bias would lead to
an underestimate of the difference between cases and
controls—thus it cannot explam the higher nsk of fetal loss
observed m the patients Most of the controls were
Partners of thrombophihc men We do not thmk their
mclusion mtroduced a bias, since the possibility that
women who choose thrombophihc men äs their partners
have an mtrmsically lower nsk of fetal loss is extremely
unlikely The frequencv of fetal loss m the control group
was similar to that in the general population ' Because of
the composition of the control group, we were able to
mvestigate the effect of paternal thrombophilia on fetal
loss, no effect was found Since this study deals with
genetic abnormalines, confoundmg bias is unlikely to be
present
In view of the well-established relation between the
thrombophihc disorders and venous thromboembohsm,
and the mcreased thrombotic nsk in people with
combmed defects, the causal mechamsm seems hkely to
involve impaired placental development and function due
to a compromised \ascular support System A similar
mechamsm has been proposed for the mcreased nsk of
fetal loss associated \\ith the presence of antibodies
directed agamst phosphohpids Similar mechanisms for
mcreased fetal loss to those reported here may operate m
women with thosc antibodies, the thrombotic risk in such
people has becn attiibuted, at least partly, to disturbances
of the protcin C piotem S pathway s This view is
strengthcned by evidtnce from an ammal model of the
importancc ot that pathway for successtul pri.gnancy
outcomc
The greatly increastd nsk of stillbirth in \\omi_n with
deficiencies of antithrombin, protein C, and protein S
strongly suggests the possibility of uteroplacental
insufficiencv äs a causative factor Another possibility is
fetal thrombosis In the group of patients some of the
women are hkely to have partners with umdentified
thrombophilia, and the fetus could then mhent genes for
famihal thrombophilia from both parents and be at
mcreased risk of venous thromboembohsm by virtue of
having combmed gene defects, or homozvgosity for factor
V Leiden '
The physiological mechanisms, mcluding the
contribution of paternal genes, for Implantation and
placental and fetal development are poorlv understood
Our results clearly indicate that the famihal thrombotic
disorders described here are not associated with female
infertihty We also provide evidence that m the context of
genetic thrombophihc disorders, the mcreased fetal losses
relate to maternal and not paternal abnormalines
The demonstration of mcreased fetal losses m women
with famihal thrombophilia, and especially m those with
combmed defects or isolated deficiencies of antithrombin,
protein C, or protein S, has important therapeutic
imphcations and provides a rationale for chmcal trials of
thromboprophylaxis for affected women with recurrent
fetal loss We must emphasise, however, that although we
have shown a significant difference m pregnancy outcome
between women with coagulation-mhibitor deficiencies
and controls, the probabihty of a favourable pregnancy
outcome is good
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